MEI Pharma (NASDAQ:MEIP) released its earnings results on Thursday. The company reported ($0.15) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.14) by ($0.01), Zacks reports. MEI Pharma had a negative return on equity of 71.32% and a negative net margin of 2,508.05%. The firm had revenue of $2.05 million for the quarter, compared to analyst estimates of $3.05 million.
NASDAQ:MEIP traded up $0.02 during trading hours on Friday, reaching $2.71. The company had a trading volume of 283,019 shares, compared to its average volume of 160,452. MEI Pharma has a 1-year low of $1.82 and a 1-year high of $5.14. The company has a market capitalization of $192.76 million, a PE ratio of -3.66 and a beta of 1.92.
A number of research firms recently commented on MEIP. BidaskClub downgraded MEI Pharma from a “hold” rating to a “sell” rating in a report on Friday, October 12th. HC Wainwright assumed coverage on MEI Pharma in a report on Thursday, December 20th. They set a “buy” rating and a $10.00 target price for the company. reissued a “buy” rating and issued a $7.50 price target on shares of MEI Pharma in a report on Monday, December 3rd. Finally, Zacks Investment Research downgraded MEI Pharma from a “buy” rating to a “hold” rating in a report on Wednesday, November 14th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and seven have given a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus price target of $8.08.
MEI Pharma Company Profile
MEI Pharma, Inc, a pharmaceutical company, focuses on the clinical development of novel therapies for the treatment of cancer. The company's clinical drug candidate includes Pracinostat, an oral available histone deacetylase inhibitor for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome.
Receive News & Ratings for MEI Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MEI Pharma and related companies with MarketBeat.com's FREE daily email newsletter.